TATVA CHINTAN PHARMA CHEM LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,020 INR | +0.05% |
|
-0.66% | -36.31% |
| 05-03 | Transcript : Tatva Chintan Pharma Chem Limited, Q4 2024 Earnings Call, May 03, 2024 | |
| 05-03 | Tatva Chintan Pharma Chem Limited Recommends Final Dividend for the Financial Year 2023-2024 | CI |
Valuation
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 51,166 | 36,995 | 23,866 | - | - |
| Enterprise Value (EV) 1 | 50,595 | 36,995 | 25,231 | 23,866 | 23,866 |
| P/E ratio | 51.8 x | 81.3 x | 81.3 x | 46.6 x | 19.7 x |
| Yield | 0.09% | - | 0.16% | 0.33% | 0.88% |
| Capitalization / Revenue | 11.8 x | 8.73 x | 6.41 x | 4.6 x | 2.85 x |
| EV / Revenue | 11.8 x | 8.73 x | 6.41 x | 4.6 x | 2.85 x |
| EV / EBITDA | 47.3 x | 61.1 x | 37 x | 24.4 x | 12.3 x |
| EV / FCF | -74.4 x | -21.1 x | 34.2 x | -74.8 x | -3,182 x |
| FCF Yield | -1.34% | -4.74% | 2.92% | -1.34% | -0.03% |
| Price to Book | 10.8 x | 7.19 x | 3.17 x | 3.06 x | 2.6 x |
| Nbr of stocks (in thousands) | 22,165 | 22,165 | 23,392 | - | - |
| Reference price 2 | 2,308 | 1,669 | 1,020 | 1,020 | 1,020 |
| Announcement Date | 4/25/22 | 5/5/23 | 5/3/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 4,336 | 4,236 | 3,935 | 5,192 | 8,373 |
| EBITDA 1 | - | 1,082 | 605.8 | 682 | 978 | 1,933 |
| EBIT 1 | - | 1,001 | 510.3 | 425.9 | 659 | 1,529 |
| Operating Margin | - | 23.07% | 12.05% | 10.82% | 12.69% | 18.26% |
| Earnings before Tax (EBT) 1 | - | 1,041 | 447.8 | 435.7 | 685 | 1,562 |
| Net income 1 | 522.6 | 958.7 | 454.9 | 303.5 | 513 | 1,211 |
| Net margin | - | 22.11% | 10.74% | 7.71% | 9.88% | 14.46% |
| EPS 2 | - | 44.59 | 20.52 | 13.26 | 21.90 | 51.77 |
| Free Cash Flow 1 | - | -687.8 | -1,753 | 698 | -319 | -7.5 |
| FCF margin | - | -15.86% | -41.39% | 17.19% | -6.14% | -0.09% |
| FCF Conversion (EBITDA) | - | - | - | 91.12% | - | - |
| FCF Conversion (Net income) | - | - | - | 207.12% | - | - |
| Dividend per Share 2 | - | 2.000 | - | 1.600 | 3.400 | 9.000 |
| Announcement Date | 9/6/21 | 4/25/22 | 5/5/23 | 5/3/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,236 | 1,047 | 985.3 | 884 | 900.9 | 1,206 | 1,245 | 1,144 | 1,155 | 1,064 | 998.2 |
| EBITDA 1 | 358.9 | 238.1 | 219.5 | 152.2 | 111.8 | 179.1 | 162.7 | 213.4 | 216 | 219.5 | 161.5 |
| EBIT 1 | - | 217.3 | 198 | 128.8 | 88.69 | 155.3 | - | 153.3 | 153 | 158 | 156 |
| Operating Margin | - | 20.76% | 20.1% | 14.57% | 9.84% | 12.88% | - | 13.41% | 13.25% | 14.85% | 15.63% |
| Earnings before Tax (EBT) | - | - | 189.8 | 137 | 90.58 | 142.2 | - | - | 139.5 | 133 | 132 |
| Net income 1 | - | - | 175.1 | 97.97 | 71.12 | 116.2 | 169.5 | 95.04 | 104 | 105.5 | 76.25 |
| Net margin | - | - | 17.77% | 11.08% | 7.89% | 9.64% | 13.62% | 8.31% | 9% | 9.92% | 7.64% |
| EPS | - | - | - | - | 3.210 | - | - | - | 4.450 | 5.500 | 4.100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/23/21 | 1/17/22 | 4/25/22 | 7/25/22 | 11/4/22 | 1/25/23 | 5/5/23 | 8/4/23 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 570 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -688 | -1,753 | 698 | -319 | -7.5 |
| ROE (net income / shareholders' equity) | - | 30% | 9.94% | 5.6% | 6.8% | 14.7% |
| ROA (Net income/ Total Assets) | - | 19.7% | 6.94% | 3.3% | 7.8% | 11.4% |
| Assets 1 | - | 4,866 | 6,555 | 10,212 | 6,577 | 10,623 |
| Book Value Per Share 2 | - | 213.0 | 232.0 | 322.0 | 334.0 | 393.0 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 892 | 2,031 | 500 | 700 | 1,054 |
| Capex / Sales | - | 20.56% | 47.95% | 12.31% | 13.48% | 12.59% |
| Announcement Date | 9/6/21 | 4/25/22 | 5/5/23 | 5/3/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,020
INR
Average target price
1,674
INR
Spread / Average Target
+64.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.31% | 286M | |
| +21.02% | 68.55B | |
| -6.50% | 46.06B | |
| +23.31% | 44.48B | |
| +31.85% | 28.5B | |
| +7.56% | 19.22B | |
| -23.96% | 15.27B | |
| -10.29% | 15.22B | |
| -28.36% | 12.17B | |
| -29.56% | 12.12B |
- Stock Market
- Equities
- TATVA Stock
- Financials Tatva Chintan Pharma Chem Limited
